MONOCLONAL ANTIIDIOTYPIC ANTIBODIES (AB2) AND THEIR USES

Anticorps monoclonaux antiidiotipiques de type IgG associés au système immunitaire, pouvant intéragir avec les lymphocytes T et B et exercer un effet immunorégulateur, une immunostimulation ou une immunosuppression pouvant être utilisés en immunothérapie de maladies auto-immunes, infectieuses et du...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	RAMOS ZAMORA, MERCEDES, BOMBINO LOPEZ, GUMERSINDA, MACIAS ABRAHAN, AMPARO EMILIA, PENA MARICHAL, ORLANDO, RODRIGUEZ OBAYA, TERESITA, PEREZ RODRIGUEZ, ROLANDO
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Anticorps monoclonaux antiidiotipiques de type IgG associés au système immunitaire, pouvant intéragir avec les lymphocytes T et B et exercer un effet immunorégulateur, une immunostimulation ou une immunosuppression pouvant être utilisés en immunothérapie de maladies auto-immunes, infectieuses et du cancer. The present invention describes the selection and use of antidiotypic monoclonal antibodies.(AB2) IgG type with the main characteristic of being highly connected to the idiotipic network and recognition of B and T human lymphocytes, which are major participants in the immune response.According to the previous statement the objective of this invention is to provide antidiotypic monoclonal antibodies IgG type connected to the immune network, able to interact with T and B lymphocytes and able to exert an immunoregulatory effect, irmunostimulation or immunosupression that can be used for immunotherapy of autoimune diseases, infectious diseases and cancer.